The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| CLARIVATE ANALYTICS PLC | *W EXP 05/13/202 | G21810117 | 7,123 | 1,235,500 | SH | SOLE | 1,235,500 | 0 | 0 | ||
| NABORS INDUSTRIES LTD | 6% PFD CNV SR A | G6359F129 | 7,682 | 339,725 | SH | SOLE | 339,725 | 0 | 0 | ||
| CRISPR THERAPEUTICS AG | NAMEN AKT | H17182108 | 4,671 | 76,700 | SH | Put | DFND | 1 | 0 | 76,700 | 0 |
| FIAT CHRYSLER AUTOMOBILES N | SHS | N31738102 | 28,057 | 1,895,604 | SH | Put | SOLE | 1,895,604 | 0 | 0 | |